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ABSTRACT 
Objective: The present study focused on solubility enhancement of the Biopharmaceutical Classification System (BCS) Class-II drug, Febuxostat 
using various super disintegrants. 
Methods: Starches were extracted from Entada scandens seed powder by alkali method i.e., sodium hydroxide at 0.1%, 0.25% and 0.5% 
concentrations and water. Starches were evaluated for various phytochemical and physicochemical tests. Solid dispersions of Febuxostat were 
prepared by fusion method using poloxamer-188 alone and by mixing poloxamer-188 with Entada scandens seed starch. Various physical 
parameters were evaluated for these solid dispersions. Tablets were prepared using Febuxostat solid dispersions and varying concentrations of 
Entada scandens seed starch by direct compression technique. Pre and post-compression parameters were evaluated along with in vitro drug 
release studies, characterization studies like Fourier Transform Infra-Red spectroscopy (FTIR), Differential Scanning Calorimetry (DSC), Scanning 
Electron Microscopy (SEM), X-Ray Diffraction (XRD) and stability studies.  
Results: Phytochemical tests revealed the presence of starch in all extracts. Starch prepared from 0.5% sodium hydroxide (ESS4) showed best 
physicochemical properties. In vitro dissolution studies revealed that solid dispersion F4 containing Febuxostat and poloxamer-188 in 1:3 ratios 
showed better drug release. Formulation FE5 containing F4 solid dispersion with 12.5% w/w of ESS4 showed enhanced drug release. FT2 tablets 
having 12.5% w/w of ESS4 showed better drug release when compared to others. FTIR and DSC studies revealed no major interactions between 
drug and excipients. XRD studies revealed the nature of formulations. Accelerated stability studies showed that all tablets were stable.  
Conclusion: The super disintegrant property of Entada scandens seed starch was evaluated. 
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Solubility is an important physicochemical factor which affects drug 
absorption and therapeutic effectiveness. Nowadays, scientists are 
focusing on the development of oral dosage forms of poor aqueous 
solubility drugs through various solubility enhancing approaches 
[1]. Among these approaches, preparation of solid dispersions is one 
of the widely used techniques. The term solid dispersion means a 
group of solid products with at least two different components, i.e., a 
hydrophilic matrix and a hydrophobic drug [2, 3]. 
Though drug administration can be made in various routes, the oral 
route is widely preferred due to its ease. But it is difficult in geriatrics and 
in children to swallow the drug. To hinder such problems, fast dissolving 
tablets (FDTs) are developed. These tablets when comes in contact with 
saliva in the mouth, they rapidly disintegrate and releases drug [4]. Fast 
dissolving tablets are widely accepted due to patient compliance, fast 
action, increased bioavailability and quick disintegration [5]. These are 
prepared by using direct compression technique. Usage of certain super 
disintegrants like sodium starch glycolate, croscarmellose, polyvinyl 
pyrrolidine, etc. provides faster tablet disintegration even at low 
concentrations. They are mixed up with a tablet and some encapsulated 
formulations which enhance the breakup of tablet and capsules “slugs” 
into smaller fragments in an aqueous environment which increases the 
available surface area. This promotes rapid drug release. They promote 
moisture penetration and dispersion of the tablet matrix [6, 7]. 
Nowadays, natural super disintegrants are preferred over synthetic 
forms, due to huge availability, economic, non-irritating and non-toxic 
properties [8]. Several gums and mucilages have super disintegrant 
property. These are useful in enhancing the water solubility of BCS Class-
II drugs. These are drugs with low solubility and high permeability 
properties. Past studies revealed the applications of components from 
plants like Ocimum tenuiflorum, mucilages of Plantago ovata, Aloe vera 
and Hibiscus rosasinesis as super disintegrants [9]. 
In the present study, an attempt was made to extract starch from of 
Entada scandens seed powder and to use it as super disintegrant for 
formulating fast-dissolving tablets. Entada scandens belonging to the 
family Fabaceae grows in evergreen tropical climates of India, Africa, 
and Australia. Their seeds have a thick and durable seed coat which 
is brownish in color. It contains a fleshy white cotyledon. These are 
rich in starch contents [10]. Febuxostat which is an anti-urolithiatic 
agent is selected as a drug candidate for the present study. It mainly 
acts by non-competitively inhibiting the enzyme xanthine oxidase. 
This prevents the conversion of hypoxanthine and xanthine to uric 
acid, thereby preventing the formation of crystals in kidneys. The 
bioavailability of Febuxostat is approximately 49%. More than 99% 
of the drug is bound to plasma proteins. It has an approximate 
elimination half-life of 5-8 h [11]. Based on pharmacokinetic and 
pharmacodynamic parameters, Febuxostat is selected as a drug of 
choice for the present study. 
MATERIALS AND METHODS 
Materials 
Febuxostat was a gift sample from Mylan Laboratories Ltd. (Hyderabad, 
India). Croscarmellose sodium was a gift sample from NATCO Pharma 
Ltd. (Hyderabad, India). Poloxamer-188 was a gift sample from Pellets 
Pharma Ltd (Hyderabad, India). Sodium hydroxide, saccharin sodium, 
magnesium stearate, and talc were procured from S.D Fine Chem. Ltd. 
(Mumbai, India). Isopropyl alcohol was obtained from High Pure Fine 
Chem. (Chennai, India). Entada scandens seeds were procured from the 
local market (Kurnool, Andhra Pradesh, India). The seeds were identified 
and authenticated by Dr. K. Ammani, Professor and Head, Department of 
Botany, Acharya Nagarjuna University, Guntur and voucher specimen 
(17/01) was preserved in Department of Pharmaceutics, Chebrolu 
Hanumaiah Institute of Pharmaceutical Sciences, Chowdavaram, Guntur, 
India. 
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Extraction of starch from Entada scandens seeds 
Entada scandens seed starch was isolated using aqueous and alkali 
extraction methods [12]. 5g Entada scandens seed flour was added into 
100 ml distilled water, 0.1%, 0.25%, and 0.5% sodium hydroxide 
solutions separately and soaked (6 h and 8 h) at room temperature then 
stirred constantly. The slurry was filtered through 212 mesh stainless 
sieve and remaining sediment was washed with distilled water three 
times. The filtrates were combined and precipitated overnight at 4 °C. 
The supernatant was discarded and the crude starch was cleaned with 
distilled water. This step was repeated three times and the starch cake 
was dried at 40 °C for 24 h in oven dryer. The starch was ground with a 
mortar and pestle. The starches were packed in a plastic bag and kept at 
room temperature until further use. 
Phytochemical tests for Entada scandens seed powder and 
extracted starches 
The raw Entada scandens seed powder and starches extracted were 
subjected to various phytochemical tests for identification of 
carbohydrates, proteins, alkaloids, glycosides, steroids, flavonoids 
and saponins [13]. The results were indicated in table 1. 
Evaluation of physicochemical properties of Entada scandens 
seed powder and extracted starches 
Various physicochemical properties like gelatinization temperature, 
pH, viscosity, swelling index, and water absorption index were 
evaluated using suitable methods [14]. 
Total microbial load of isolated Entada scandens starch 
The total microbial load is an important parameter which decides 
the suitability of a substance for use as an excipient in the 
pharmaceutical dosage form. The starch powders were subjected to 
dry heat sterilization at 180 °C for 30 min. Then the starches were 
inoculated on medium and were incubated for 24 h. Then the 
colonies were counted using a microbial colony counter. The results 
were indicated in table 2. 
Preparation of febuxostat solid dispersions by fusion method 
Solid dispersions of Febuxostat were prepared using Poloxamer-188 
in different ratios by fusion method. Poloxamer-188 was placed in 
china dish and heated at 40 °C until it gets melted and then 
Febuxostat was added to it. After vigorous stirring in normal 
temperature, the mixture gets solidified. The solid mass was 
crushed, pulverized and sieved. The granules obtained were stored 
in a desiccator for further studies. The results were given in table 3. 
Preparation of febuxostat solid dispersions by fusion method 
using Entada scandens seed starch 
After performing dissolution studies for Solid dispersions of Febuxostat, 
the formulation showing best dissolution profile was selected. To that 
formulation, Entada scandens seed starch (ESS4) was added in 
increasing concentrations i.e., 2.5, 5.0, 7.5, 10.0, 12.5 and 15.0 by keeping 
the optimized formulation constant. The optimized formulation was 
placed in a china dish and heated at 40 °C until it gets melted and then 
ESS4 was added to it. After vigorous stirring in normal temperature, the 
mixture gets solidified. The solid mass was crushed, pulverized and 
sieved. The granules obtained were stored in a desiccator for further 
studies. The results were given in table 4. 
Evaluation of physical parameters 
The prepared solid dispersions were evaluated for various physical 
parameters such as the angle of repose, Carr’s index, Hausner's ratio, 
particle size and drug content [11]. The results were indicated in table 5. 
In vitro dissolution studies 
Dissolution studies for all solid dispersions were performed in a 
calibrated 8 station dissolution test apparatus (LABINDIA DS8000) 
equipped with paddles employing 900 ml of 0.05M phosphate buffer 
pH 6.0 as dissolution medium. The paddles were operated at 50 rpm 
and the temperature was maintained at 37±1° C throughout the 
experiment [15]. The samples were withdrawn at 5, 10, 15, 20 and 
30 min and replaced with an equal volume of same dissolution 
medium to maintain the sink conditions throughout the experiment. 
Samples withdrawn were suitably diluted with same dissolution 
medium and the amount of the drug dissolved was estimated by Lab 
India double beam U. V spectrophotometer (UV 3000+) at 315 nm. 
The dissolution profiles were indicated in tables 6 and 7. 
Preparation of febuxostat tablets 
Febuxostat tablets were prepared by direct compression technique. The 
drug concentration was maintained constant, while the optimized solid 
dispersion concentration was increased. The raw materials were 
individually weighed and were then converted into damp mass by using 
isopropyl alcohol. The damp mass was passed through sieve no 20 to 
obtain granules and they were kept for drying. The prepared granules 
were passed through sieve no. 40. The granules were taken into a plastic 
bag and lubricated with 1% talc, magnesium stearate and half of the 
starch. Then they were compressed as tablets using CLIT 10 station 
mini-press. To minimize the processing variables all batches of tablets 
were compressed, under identical conditions. The compositions of 
various tablet formulations were given in table 8. To minimize the 
processing variables, all batches of tablets were compressed under 
identical conditions.  
Evaluation of pre-compression parameters 
The prepared granules were evaluated for pre-compression 
parameters such as the angle of repose, Carr’s index and Hausner's 
ratio [16]. The results were given in table 9. 
Evaluation of post-compression parameters 
The compressed tablets were further evaluated for post-
compression parameters such as weight uniformity, hardness, 
friability, wetting time, dispersion test and drug content [17]. The 
results were given in table 10. 
In vitro dissolution studies of Febuxostat tablets 
Dissolution studies for tablet formulations were performed in a 
calibrated 8 station dissolution test apparatus (LAB INDIA DS8000) 
equipped with paddles (USP apparatus II method) employing 900 ml of 
0.05M phosphate buffer pH 6.0 as dissolution medium. The paddles were 
operated at 50 rpm and the temperature was maintained at 37±1° C 
throughout the experiment. The samples were withdrawn at 5, 10, 15, 
20 and 30 min and replaced with an equal volume of same dissolution 
medium to maintain the constant volume throughout the experiment. 
Samples were suitably diluted with same dissolution medium and the 
amount of drug dissolved was estimated by Lab India double beam U. V 
spectrophotometer (UV 3000+) at 315 nm. The dissolution profiles were 
given in table 11. 
Characterization studies 
Based on dissolution studies, the optimized formulations were 
subjected to FTIR and DSC studies to observe the drug-polymer 
interactions. X-Ray Diffraction (XRD) studies were performed to 
detect the nature of formulations. Scanning electron microscopy 
(SEM) analysis was performed to know surface characteristics. The 
results were shown in fig. 1, 2, 3 and 4. 
Accelerated stability studies 
Accelerated stability studies were carried out on optimized 
formulations as per International Council for Harmonisation of 
Technical Requirements for Registration of Pharmaceuticals for 
Human Use (ICH) guidelines. These studies were carried out to 
investigate the effect of temperature on the physical properties and 
drug release of the tablets. The results were given in table 12. 
RESULTS AND DISCUSSION 
Extraction of starch from Entada scandens seeds 
The starches extracted from Entada scandens seed powder were 
crisp, slightly granular, free-flowing and stable in nature. 
Phytochemical screening of Entada scandens seed flour and 
starch extracts  
The raw Entada scandens seed powder and starches extracted were 
screened for the presence of various phytochemical constituents. 
The results were indicated in table 1. 
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Table 1: Phytochemical screening of Entada scandens seed powder and starches 
Test ESSP ESS1 ESS2 ESS3 ESS4 
Carbohydrates + + + + + 
Polysaccharides + + + + + 
Proteins + – – – – 
Alkaloids + – – – – 
Glycosides – – – – – 
Steroids + – – – – 
Flavonoids + – – – – 
Saponins + – – – – 
+indicates present; –indicates absent 
 
Physicochemical parameters of Entada scandens seed flour and 
starch extracts  
Physicochemical parameters were evaluated for all the starches. The 
results were indicated in table 2. The starch ESS4 showed high 
swelling index and water absorption index which made it suitable 
for selection of solid dispersions and tablets. 
Preparation of febuxostat solid dispersions by fusion method 
Solid dispersions of Febuxostat were prepared using poloxamer-188 
as a carrier in different ratios by fusion method. The composition 
was given in table 3. 
Evaluation of physical parameters 
Various physical parameters of Febuxostat solid dispersions were 
evaluated. The obtained results were indicated in table 5. 
In vitro dissolution studies of febuxostat solid dispersions 
Formulation F4, prepared in 1:3 ratios of Febuxostat and Poloxamer-
188 showed maximum drug release proving that solid dispersion 
technique enhances drug release as suggested by the earlier studies 
[18, 19]. The dissolution profiles of Febuxostat solid dispersions 
were given in table 6. 
 
Table 2: Physico-chemical properties of Entada scandens seed powder and starches 
Properties ESSP ESS1 ESS2 ESS3 ESS4 
Gelatinization temperature  218-226 °C 220-229 °C 222-226 °C 224-227 °C 226-229 °C 
pH 6.34 6.51 6.67 6.80 6.99 
Viscosity (in cps) 1.845 2.152 2.210 2.421 2.508 
Swelling index 68 72 79 83 87 
Water Absorption Index Less More More More More 
Total Microbial Load Absent Absent Absent Absent Absent 
 
Table 3: Composition of febuxostat solid dispersions prepared by fusion method 









*One part is equal to 40 mg, similarly, solid dispersions were prepared by fusion method using Entada scandens seed starch (ESS4) as a carrier in 
different ratios with a constant amount of optimized formulation (F4). The composition was given in table 4. 
 
Table 4: Composition of febuxostat solid dispersions prepared by fusion method using F4 and Entada scandens seed starch (ESS4) 










Table 5: Physical parameters of febuxostat solid dispersions 
Solid dispersion Angle of repose ( °) Carr’s index (%) Hausner's ratio Average particle 
size (μm) 
Drug content (mg) 
(mean±SEM) 
FP 35 21 1.28 41 37.32±0.55 
F1 26 17 1.22 180 34.14±0.21 
F2 25 16 1.19 174 36.84±0.68 
F3 23 14 1.17 177 37.72±0.92 
F4 21 12 1.15 167 39.90±0.57 











































*FP indicates Febuxostat pure drug; n=3, SEM: standard error of mean 
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Table 6: Drug release profiles of febuxostat solid dispersions prepared by fusion method 
Time  
(min) 
Cumulative % drug released (mean±SEM) 
FP F1 F2 F3 F4 F5 F6 
5 2.21±1.01 37.42±1.09 41.91±0.55 50.82±1.08 51.92±1.84 45.97±1.14 36.19±1.19 
10 5.27±0.95 42.27±1.45 47.28±0.81 53.55±1.88 62.50±1.11 50.51±0.32 48.58±1.62 
15 11.29±0.84 47.71±0.88 52.71±1.06 59.70±0.74 69.02±1.71 58.70±1.51 55.71±1.04 
20 14.38±1.15 52.76±1.14 59.37±1.15 67.25±1.38 73.42±0.81 66.02±1.66 63.63±0.87 
30 19.56±1.07 54.43±1.60 62.44±1.66 69.31±0.50 75.80±0.67 70.80±2.02 68.55±1.27 
n=3, SEM: standard error of the mean 
 
Whereas formulation FE5, prepared with F4 and 12.5%w/w of ESS4 
showed maximum drug release. The fusion technique used for the 
formulation of solid dispersions was also proved to be most 
advantageous as suggested earlier [20]. The dissolution profiles of 
Febuxostat solid dispersions were given in table 7. 
Preparation of febuxostat tablets 
Febuxostat tablets with various concentrations of Entada 
scandens seed starch (ESS4) and croscarmellose sodium (CCS) 
were prepared by direct compression technique. Formulations 
FT1 to FT3 were prepared using 10.0 to 15% of alkali extracted 
starch (ESS4). Formulations FT4 to FT6 were prepared using 
10.0 to 15% of CCS. Whereas the formulation FTP doesn’t 
contain only the solid dispersion FE5. The compositions were 
given in table 8. 
Evaluation of pre-compression parameters 
The pre-compression parameter values obtained for various 
prepared granules were given in table 9. The angle of repose, Carr’s 
index, and Hausner’s ratio values for granules were within the range 
specified. Thus all the prepared granules were found to be stable and 
suitable for compression of tablets. 
 
Table 7: Drug release profiles of febuxostat solid dispersions prepared by fusion method using F4 and Entada scandens seed starch 
Time  
(min) 
 Cumulative % drug released (mean±SEM) 
FP FE1 FE2 FE3 FE4 FE5 FE6 
5 2.21±1.01 71.24±1.42 74.94±0.42 79.81±1.51 76.54±1.47 81.72±1.24 70.12±1.49 
10 5.27±0.95 84.71±1.08 86.20±0.91 89.63±1.98 90.07±0.91 94.22±1.78 81.44±1.37 
15 11.29±0.84 91.08±0.91 93.88±1.65 95.77±0.69 95.73±1.67 98.67±1.99 85.52±1.11 
20 14.38±1.15 93.11±1.54 95.37±1.07 97.61±1.37 96.25±1.83 99.81±1.65 87.61±0.69 
30 19.56±1.07 94.31±1.11 96.63±1.52 98.24±0.73 97.48±1.06 99.91±0.82 88.97±1.07 
n=3, SEM: standard error of the mean 
 
Table 8: Composition of febuxostat tablets with different polymer concentrations 
Ingredient (mg/tablet) Formulations  
FTP FT1 FT2 FT3 FT4 FT5 FT6 
FE5 Solid Dispersion 180 180 180 180 180 180 180 
Spray Dried Lactose 112.5 82.50 75.0 67.50 82.50 75.0 67.50 
ESS4 ----- 30.0 37.50 45.0 ----- ----- ----- 
CCS ----- ----- ----- ----- 30.0 37.50 45.0 
Saccharin Sodium 5 5 5 5 5 5 5 
Isopropyl Alcohol Q. S Q. S Q. S Q. S Q. S Q. S Q. S 
Lemon Flavour Q. S Q. S Q. S Q. S Q. S Q. S Q. S 
Talc 1.25 1.25 1.25 1.25 1.25 1.25 1.25 
Magnesium Stearate 1.25 1.25 1.25 1.25 1.25 1.25 1.25 
Total Weight 300 300 300 300 300 300 300 
Q. S indicates quantity sufficient 
 
Table 9: Pre-compression parameters of granules prepared for tablet formulations 
Formulation Angle of repose ( °) Carr’s index (%) Hausner’s ratio 
FTP 30 19 1.20 
FT1 24 14 1.15 
FT2 23 12 1.13 
FT3 25 13 1.14 
FT4 26 15 1.16 
FT5 23 12 1.13 
FT6 25 14 1.15 
 
Evaluation of post-compression characteristics of febuxostat 
tablets 
The direct compression method was found to be suitable for 
preparation of fast dissolving tablets. All the batches of tablets were 
compressed under identical conditions to minimize processing 
variables. They were evaluated for post-compression parameters 
such as weight uniformity, hardness, friability, wetting time, 
dispersion test and drug content. The results were given in table 10. 
Weight uniformity, hardness and friability loss of tablet formulations 
were within the specified limits and were found to be stable and 
suitable for further studies. 
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Table 10: Post compression parameters of various febuxostat tablet formulations 












FTP 297±1.05 3.3±0.82 0.3 210 Passed 36.64±1.08 
FT1 299±1.42 3.2±1.48 0.3 74 Passed 40.71±0.97 
FT2 300±0.88 3.0±1.03 0.2 60 Passed 40.22±1.56 
FT3 298±1.07 3.2±0.65 0.4 69 Passed 38.49±1.22 















n=6; SEM is the standard error of the mean 
 
In vitro dissolution studies of febuxostat tablets 
Dissolution studies were carried on Febuxostat tablets using U. S. P 
paddle method (apparatus II) with 0.05M phosphate buffer pH 6.0 as 
dissolution medium by maintaining the bath temperature at 37+1 °C 
and the paddles were operated at 50 rpm. The dissolution profiles of 
tablets were given in table 11. It was observed that the proportion of 
starch as super disintegrant has greatly influenced the dissolution 
parameters of various formulations. Formulation FT2 containing 
12.5% w/w of ESS4 as super disintegrant exhibited closer 
dissolution profile with that of formulation FT5 prepared by 12.5% 
w/w of CCS. Several studies have been carried out previously 
indicating the advantages of super disintegrants in solubility 
enhancement [21]. Those studies suggest the usage of a mixture of 
super disintegrants rather than single [22]. Recent works focus on 
the natural starches application as super disintegrants [23, 24]. They 
have successfully proved the efficacy of natural starches as 
pharmaceutical excipients. 
 
Table 11: Dissolution profiles of febuxostat tablets prepared by direct compression method (FT1–FT6) 
Time (min)  Cumulative % drug released (mean±SEM) 
FTP FT1 FT2 FT3 FT4 FT5 FT6 
5 36.22±0.84 88.08±1.27 89.79±1.82 86.43±1.91 86.04±1.57 88.91±1.06 86.37±1.64 
10 39.45±1.06 94.19±1.89 97.87±1.24 92.81±1.37 92.57±1.72 95.12±1.31 92.13±1.22 
15 44.46±1.47 98.26±2.01 99.46±1.94 96.17±1.49 96.31±1.18 97.67±1.45 93.66±1.19 
20 57.61±1.62 98.97±1.87 99.50±1.31 97.41±1.22 97.62±1.44 98.32±1.76 94.74±2.11 
30 65.56±1.37 99.38±1.66 99.68±1.28 98.88±1.06 97.91±1.65 99.09±1.37 95.81±1.08 
n=3; SEM is the standard error of the mean 
 
Characterization of febuxostat fast dissolving tablets 
FT-IR spectra 
The FT-IR spectral investigations were carried out on pure drug of 
Febuxostat, ESS4, CCS, poloxamer-188, sold dispersions F4 and 
FE5, fast dissolving tablets of Febuxostat FT2 and FT5. Febuxostat 
pure drug exhibited sharp peaks at 2228.03 cm-1, 1682.28 cm-1, 
1011.49 cm-1 and 767.05 cm-1indicating the presence of C=C 
stretching,-C=O stretching,-C=N-stretching, ≡C-O-stretching and–
N=H wag. Starch extracted from Entada scandens, ESS4 exhibited 
sharp peaks at 3049.42 cm-1, 1645.74 cm-1, 1242.69 cm-1and 
1014.79 cm-1 indicating the presence of ≡ C-H stretching, C=O 
stretching, C-H wag, and ≡C-O-stretching. Whereas CCS exhibited 
sharp peaks at 1409.53 cm-1, 1059.82 cm-1 and 897.37 cm-1 
indicating the presence of-C≡N bending,-C=N-stretching and ≡C-H 
bending. Poloxamer-188 exhibited sharp peaks at 2237.60 cm-1, 
1643.70 cm-1, 1407.39 cm-1 and 1281.02 cm-1 indicating the 
presence of C=C stretching,-C=O stretching,-C≡N bending and C-H 
wag. Formulation F4, solid dispersion made with Febuxostat and 
poloxamer-188 in 1:3 ratio exhibited strong peaks at 2231.37 cm-1, 
1679.53 cm-1, 1402.12 cm-1, 1274.50 cm-1, 1011.81 cm-1 and 
762.71 cm-1 indicating the presence of C=C stretching,-C=O 
stretching,-C≡N bending, C-H wag, ≡C-O-stretching and–N=H wag. 
Formulation FE5, solid dispersion made with F4 and 12.5%w/w 
ESS4 exhibited strong peaks at 2230.92 cm-1, 1609.65 cm-1, 
1275.84 cm-1, and 763.49 cm-1 indicating the presence of C=C 
stretching,-C=O stretching, C-H wag and–N=H wag. FT2, an FDT 
prepared with Febuxostat, FE5 and 12.5%w/w ESS4 exhibited 
peaks at 2230.44 cm-1, 1656.80 cm-1, 949.23 cm-1 and 763.99 cm-1 
indicating the presence of C=C stretching,-C=O stretching,-O-H 
bending and–N=H wag. FT5, an FDT prepared with Febuxostat, 
FE5 and 12.5%w/w CCS exhibited peaks at 1638.13 cm -1, 1413.59 
cm-1 and 1059.33 cm-1 indicating the presence of-C=O stretching,-
C≡N bending and-C≡N stretching. The detailed spectral 
elucidations were shown in fig. 1. 
DSC thermograms 
The DSC thermographic studies were carried out on pure drug of 
Febuxostat, ESS4, CCS, poloxamer-188, sold dispersions F4 and FE5, 
fast dissolving tablets of Febuxostat FT2 and FT5. These studies 
exhibited broad endothermic peaks at 217.42 °C, 266.29 °C and 
303.83 °C for Febuxostat pure drug, a broad endothermic peak at 
311.1 °C for ESS4, a sharp endothermic peak at 59.06 °C for 
poloxamer-188, a sharp exothermic peak at 319.1 °C for CCS, broad 
endothermic peaks at 60.70 °C and 307.55 °C for F4 solid dispersion, 
broad endothermic peaks at 58.69 °C, 236.64 °C and 301.53 °C for 
FE5 solid dispersion which has ESS4. Broad endothermic peaks were 
observed at 57.94 °C, 222.45 °C, 230.25 °C, and 302.66 °C for 
formulation FT2, which is an FDT made with Febuxostat and ESS4 
along with FE5. A sharp endothermic peak at 270.12 °C, a broad 
endothermic peak at 312.82 °C and a sharp exothermic peak at 
376.55 °C were observed for formulation FT5, which is an FDT made 
with Febuxostat and CCS along with FE5. It was observed that there 
is a slight shift in temperature for drug and CCS. The detailed 
thermographs were shown in fig. 2. 
SEM studies 
Scanning electron microscopy images were taken for Febuxostat pure 
drug, ESS4, CCS, poloxamer-188, a blend of Febuxostat with 
poloxamer-188, Febuxostat with poloxamer-188 and ESS4 and 
Febuxostat with poloxamer-188 and CCS. Febuxostat pure drug 
exhibited crystalline form. The ESS4 starch exhibited a free-flowing 
spherical low dense form of starch grains without any 
mucilage/resinous coverage. Poloxamer-188 exhibited clear spherical 
granules. CCS exhibited blunt tubular-shaped crystals. The SEM image 
of Febuxostat with ESS4 clearly exhibited uniform dispersion of drug 
with spherical globular starch grains. The SEM image of Febuxostat 
with ESS4 and poloxamer-188 showed complete dispersion of drug 
with both the polymers. The SEM image of Febuxostat with CCS 
showed uniform dispersion of drug with blunt tubular crystals of CCS. 
The detailed SEM images were shown in fig. 3. 
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(G)      (H) 
Fig. 1: FT-IR spectra: (A) Febuxostat pure drug (B) ESS4 (C) Poloxamer-188 (D) CCS, (E) F4 (F) FE5 (G) FT2 (H) FT5, ESS4–Entada scandens 
seed starch extracted by 0.5% sodium hydroxide; CCS–Croscarmellose sodium; F4–Febuxostat and poloxamer-188 solid dispersion in 1:3 
ratio; FE5–F4 solid dispersion with 12.5% w/w of ESS4; FT2–Febuxostat FDT with 12.5% w/w of ESS4; FT5-Febuxostat FDT with 12.5% 
w/w of CCS 
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(G)      (H) 
Fig. 2: DSC thermograms: (A) Febuxostat pure drug (B) ESS4 (C) Poloxamer-188, (D) CCS (E) F4 (F) FE5 (G) FT2 (H) FT5, ESS4–Entada 
scandens seed starch extracted by 0.5% sodium hydroxide; CCS–Croscarmellose sodium; F4–Febuxostat and poloxamer-188 solid 
dispersion in 1:3 ratio; FE5–F4 solid dispersion with 12.5% w/w of ESS4; FT2–Febuxostat FDT with 12.5% w/w of ESS4; FT5–Febuxostat 
FDT with 12.5% w/w of CCS 
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(G) 
Fig. 3: SEM images: (A) Febuxostat pure drug (B) ESS4 (C) Poloxamer-188, (D) CCS (E) A blend of Febuxostat with poloxamer-188 (F) A 
blend of Febuxostat with poloxamer-188 and ESS4 (G) A blend of Febuxostat with CCS, ESS4–Entada scandens seed starch extracted by 
0.5% sodium hydroxide; CCS–Croscarmellose sodium 
 
X-ray diffractograms 
XRD diffraction studies were carried out for pure drug of Febuxostat, 
ESS4, CCS, poloxamer-188, Sold dispersions F4 and FE5, fast 
dissolving tablets of Febuxostat FT2 and FT5. The X-ray 
diffractogram of Febuxostat showed sharp and intense peaks at 
diffraction angles (2θ) of 12.082, 25.360 ° and 26.220 ° indicating a 
typical crystalline pattern. Whereas ESS4 showed intense peaks at 
diffraction angles (2θ) of 17.730°, 24.251°, and 33.531 °. Poloxamer-
188 showed sharp peaks at diffraction angles (2θ) of 18.214 °, 
23.341° and 27.127° CCS showed sharp and intense peaks at 
diffraction angles (2θ) of 21.770°, 22.741°, 25.292° and 30.210 ° 
indicating crystalline nature. Formulation, F4 which is a solid 
dispersion of Febuxostat and poloxamer-188 showed sharp and 
intense peaks at diffraction angles (2θ) of 13.102 °, 19.317 °, and 
23.445 ° indicating the disappearance of some of the crystalline 
peaks of drug and poloxamer-188. Formulation, FE5 which is a solid 
dispersion of Febuxostat and poloxamer-188 with ESS4 showed 
sharp and intense peaks at diffraction angles (2θ) of 13.108°, 
19.330°, and 23.497° indicating the disappearance of some of the 
crystalline peaks of the drug, poloxamer-188, and ESS4. This shows 
the formation of a new solid phase. Formulation, FT2 which is an 
FDT of Febuxostat and ESS4 showed sharp and intense peaks at 
diffraction angles (2θ) of 18.240 °, 19.800 °, and 21.054 ° indicating 
the disappearance of most of the crystalline peaks of drug and ESS4. 
Formulation, FT5 which is an FDT of Febuxostat and CCS showed 
sharp and intense peaks at diffraction angles (2θ) of 13.024 °, 22.547 
°, and 26.334 ° indicating the disappearance of most of the 
crystalline peaks of drug and CCS. This suggests the formation of a 
new solid phase with a lower degree of crystallinity due to 
complexation. The detailed diffractograms were shown in fig. 4. 
Accelerated stability studies of Febuxostat fast dissolving tablets 
The fast-dissolving tablets FT2 and FT5 containing Febuxostat with 
FE5 solid dispersion mixed with ESS4 and CCS in 12.5% w/w 
respectively showed well in vitro dissolution and so was subjected to 
accelerated stability studies. The results were indicated in table 12. 
The results showed that there were no visible and physical changes 
observed in the FDTs after storage. Weight uniformity, hardness, 
friability, wetting time, dispersion test and drug content were found 
to be uniform before and after storage at different conditions. It was 
also observed that there was no significant change in drug release 
from the FDTs. Thus the drug release characteristics of FDTs 
designed were found to be quite stable. 
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Fig. 4: XRD diffractograms: (A) Febuxostat pure drug (B) ESS4 (C) Poloxamer-188, (D) CCS (E) F4 (F) FE5 (G) FT2 (H) FT5, ESS4–Entada 
scandens seed starch extracted by 0.5% sodium hydroxide; CCS–Croscarmellose sodium; F4–Febuxostat and poloxamer-188 solid 
dispersion in 1:3 ratio; FE5–F4 solid dispersion with 12.5% w/w of ESS4; FT2–Febuxostat FDT with 12.5% w/w of ESS4; FT5-Febuxostat 
FDT with 12.5% w/w of CCS 
 
Table 12: Post compression parameters of FT2 and FT5 under accelerated stability conditions 




Dispersion test Wetting time (sec) Drug content (mg/tablet) 
mean±SEM 
FT2 Before Storage 3.0±1.03 0.2 Passed 60 40.22±1.56 
25±2 °C, 60±5% RH 3.0±1.12 0.3 Passed 62 40.10±1.24 
40±2 °C, 75±5% RH 3.1±1.01 0.2 Passed 62 40.19±1.77 
FT5 Before Storage 3.0±1.11 0.2 Passed 64 40.32±1.73 
25±2 °C, 60±5% RH 3.1±1.54 0.3 Passed 66 40.05±0.98 
40±2 °C, 75±5% RH 3.0±1.16 0.3 Passed 65 40.21±1.91 
n=3; SEM is the standard error of the mean 
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CONCLUSION 
The current study shows that the proportion of starch as super 
disintegrant has greatly influenced the dissolution parameters of 
various formulations. Similar dissolution profiles were observed for 
formulations, FT2 containing 12.5%w/w of ESS4 and FT5 containing 
12.5%w/w of CCS as super disintegrants. The super disintegrant effect 
of these starches might be due to the rapid uptake of water, followed 
by swelling that leads to an increase in hydrostatic pressure of tablet 
that ultimately disintegrates tablets faster. The optimized formulations 
showed no drug-excipient interactions when subjected to FTIR and 
DSC analysis. Similarly, crystallinity was observed using XRD studies. 
The formulations FT2 and FT5 were also found to be stable even when 
subjected to accelerated stability studies. 
Based on the above studies, it was concluded that Febuxostat fast 
dissolving tablets prepared by Entada scandens seed starch 
extracted from 0.5% sodium hydroxide showed rapid drug release. 
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